Literature DB >> 26782669

Partial liver resection results in a significantly better long-term survival than locally ablative procedures even in elderly patients.

A Bauschke1, A Altendorf-Hofmann2, H Mothes2, F Rauchfuß2, U Settmacher2.   

Abstract

PURPOSE: The number of elderly patients with HCC will increase worldwide in the next years. Therefore, surgeons need to reassess clinical algorithms for the treatment of patients with HCC. We reevaluated a cohort of patients treated in the last 10 years at our hospital, with emphasis on long-term results and age.
METHOD: A prospectively recorded consecutive series of all patients treated in between January 1995 and December 2014 with curative intent either by partial liver resection or by ablative therapy was analysed.
RESULTS: At the time of diagnosis, 232 patients were younger than 70 years and 127 patients were aged 70 years and over. In the latter group, solitary tumours, absence of liver cirrhosis and resection therapy were more frequent compared to younger patients. Charlson index, AFP-negative tumours and CLIP score were equally distributed in both groups. Observed survival of older and younger patients was similar but after partial liver resection, younger patients had a better survival than elderly patients, whereas survival in patients treated with ablation was similar in both groups. In the univariate analysis, long-term survival of patients aged 70 years and over was influenced by treatment procedure, number of lesions, liver cirrhosis, Child's stage and CLIP score. In the multivariate analysis, only treatment procedure and CLIP score were identified as independent predictors of observed survival, and comorbidity was not.
CONCLUSION: In patients aged 70 years and over, long-term prognosis is independently influenced by CLIP score and treatment procedure and other findings have only minor influence on long-term survival.

Entities:  

Keywords:  Elderly patient; HCC; Liver resection; Survival

Mesh:

Year:  2016        PMID: 26782669     DOI: 10.1007/s00432-016-2115-6

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  34 in total

1.  Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy.

Authors:  Wei-Yu Kao; Yi-You Chiou; Hung-Hsu Hung; Chien-Wei Su; Yi-Hong Chou; Teh-Ia Huo; Yi-Hsiang Huang; Wen-Chieh Wu; Han-Chieh Lin; Shou-Dong Lee; Jaw-Ching Wu
Journal:  J Clin Gastroenterol       Date:  2012-01       Impact factor: 3.062

2.  Hepatic resection is justified for elderly patients with hepatocellular carcinoma.

Authors:  Kazuhiro Kondo; Kazuo Chijiiwa; Mayumi Funagayama; Masahiro Kai; Kazuhiro Otani; Jiro Ohuchida
Journal:  World J Surg       Date:  2008-10       Impact factor: 3.352

3.  Hepatic resection for hepatocellular carcinoma in the elderly.

Authors:  Masaki Kaibori; Kosuke Matsui; Morihiko Ishizaki; Takamichi Saito; Hiroaki Kitade; Yoichi Matsui; A-Hon Kwon
Journal:  J Surg Oncol       Date:  2009-03-01       Impact factor: 3.454

4.  Factors affecting survival and long-term outcome in the cirrhotic patient undergoing hepatic resection for hepatocellular carcinoma.

Authors:  A Chiappa; A P Zbar; R A Audisio; B E Leone; F Biella; C Staudacher
Journal:  Eur J Surg Oncol       Date:  2000-06       Impact factor: 4.424

5.  Surgical outcomes and prognostic factors in elderly patients (75 years or older) with hepatocellular carcinoma who underwent hepatectomy.

Authors:  Nobuhiko Taniai; Hiroshi Yoshida; Masato Yoshioka; Youichi Kawano; Eiji Uchida
Journal:  J Nippon Med Sch       Date:  2013       Impact factor: 0.920

6.  In-hospital mortality from liver resection for hepatocellular carcinoma: a simple risk score.

Authors:  Jessica P Simons; Sing Chau Ng; Joshua S Hill; Shimul A Shah; Zheng Zhou; Jennifer F Tseng
Journal:  Cancer       Date:  2010-04-01       Impact factor: 6.860

7.  Hepatocellular carcinoma in the elderly: results of surgical and nonsurgical management.

Authors:  R T Poon; S T Fan; C M Lo; C L Liu; H Ngan; I O Ng; J Wong
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 9.  Treatment for hepatocellular carcinoma in elderly patients: a literature review.

Authors:  Hiroki Nishikawa; Toru Kimura; Ryuichi Kita; Yukio Osaki
Journal:  J Cancer       Date:  2013-09-14       Impact factor: 4.207

10.  Uncompromised treatment efficacy in elderly patients with hepatocellular carcinoma: a propensity score analysis.

Authors:  Po-Hong Liu; Chia-Yang Hsu; Yun-Hsuan Lee; Cheng-Yuan Hsia; Yi-Hsiang Huang; Chien-Wei Su; Yi-You Chiou; Han-Chieh Lin; Teh-Ia Huo
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

View more
  4 in total

1.  Perioperative Outcomes of Laparoscopic Minor Hepatectomy for Hepatocellular Carcinoma in the Elderly.

Authors:  Brian K P Goh; Darren Chua; Nicholas Syn; Jin-Yao Teo; Chung-Yip Chan; Ser-Yee Lee; Prema Raj Jeyaraj; Peng-Chung Cheow; Pierce K H Chow; London L P J Ooi; Alexander Y F Chung
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

2.  The Age-Adjusted Charlson Comorbidity Index Predicts Prognosis in Elderly Cancer Patients.

Authors:  Shi Zhou; Xing-Hu Zhang; Yuan Zhang; Ge Gong; Xiang Yang; Wen-Hui Wan
Journal:  Cancer Manag Res       Date:  2022-05-06       Impact factor: 3.602

3.  Radiofrequency ablation versus surgical resection in elderly patients with early-stage hepatocellular carcinoma in the era of organ shortage.

Authors:  Bin Yu; Youming Ding; Xiaofeng Liao; Changhua Wang; Bin Wang; Xiaoyan Chen
Journal:  Saudi J Gastroenterol       Date:  2018 Nov-Dec       Impact factor: 2.485

4.  Surgical resection vs radiofrequency ablation in older adults with early stage hepatocellular carcinoma: Where do we stand?

Authors:  Bandar Al-Judaibi; M Katherine Dokus
Journal:  Saudi J Gastroenterol       Date:  2018 Nov-Dec       Impact factor: 2.485

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.